14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 62 days ( 0 % )
Last Price $12.01 0 %
High/ Low $12.01 - $12.01 0%
Chg 7 Days N/A $12.01 $12.01
Chg 30 Days N/A $12.01 $12.01
Chg 12 mos 22.55 % $9.80 $12.01
Trend - 3 mos N/A Width: 0.00000000 %
Trend - 12 mos 51.91 % Width: 179.63 %
Pred. range - 3 mos $12.01 - $12.01 0 % - 0 %
Pred. range - 12 mos $11.62 - $32.50 -3.22 % - 170.62 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Buy Nov 29, 2023 - 60 days
Short MA avg 12 mos Buy Nov 22, 2023 - 64 days
Long MA avg 12 mos Buy Jan 22, 2024 - 25 days
Short/Long MA avg 12 mos Buy Jan 22, 2024 - 25 days
Pivot Short Sell Feb 23, 2024 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Aeglea BioTherapeutics

Aeglea BioTherapeutics Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, w... AGLE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT